Evicenter
Ibrance (palbociclib) in HR-positive HER2-negative advanced or metastatic breast cancer
Manufacturer
Pfizer Laboratories Div Pfizer Inc
Questions
28
Last updated

All questions

Safety: Ibrance (palbociclib) in HR-positive HER2-negative advanced or metastatic breast cancer

9 questions · 3 sources

Side effects

What are the most common side effects of Ibrance with letrozole (PALOMA-2)?

Applies to PALOMA-2: postmenopausal women with ER-positive, HER2-negative advanced breast cancer and no prior systemic treatment for advanced disease (IBRANCE plus letrozole vs placebo plus letrozole)

What are the most common side effects of Ibrance with fulvestrant (PALOMA-3)?

Applies to PALOMA-3: women with HR-positive, HER2-negative advanced breast cancer whose disease progressed on or after prior endocrine therapy (IBRANCE plus fulvestrant vs placebo plus fulvestrant)

What blood test abnormalities occur with Ibrance (PALOMA-2 and PALOMA-3)?

Does Ibrance cause nosebleeds, dry eye, or blurred vision?

How often did side effects lead to stopping Ibrance (PALOMA-2, PALOMA-3)?

Warnings

How common is neutropenia (low neutrophil count) with Ibrance?

Can Ibrance cause lung problems (ILD or pneumonitis)?

Safety management

How often did neutropenia lead to Ibrance dose changes (PALOMA-2, PALOMA-3)?

Was G-CSF allowed for neutropenia in the Ibrance PALOMA-2 and PALOMA-3 trials?